Urogen Pharma Ltd (URGN) - News Archive

UroGen Pharma Reaches Major Milestone in Fight Against Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., July 07, 2025 UroGen Pharma Ltd. (Nasdaq: URGN), a pioneering biotech company focused on developing innovative t...

In an era where precision medicine is increasingly at the forefront of cancer treatment, UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from the subgroup analyses of its pivotal ENVISION trial. This...

Navigating the Tumultuous Waters of Biotech: UroGen’s Resilience and Innovation Amidst Market Challenges In the dynamic and rapidly evolving world of biotechnology, the journey from research and development to commercia...

UGN-102: A Promising New Approach in the Fight Against Bladder Cancer UroGen Pharma Ltd. a pioneering biotech company in the field of urothelial and specialty cancer treatments, has been making significant strides with...

Breakthrough in Urothelial Cancer: UGN-102 Shows Potential as First FDA-Approved Treatment for LG-IR-NMIBC In a promising stride for urothelial cancer treatment, UroGen Pharma Ltd. (NASDAQ: URGN) has announced impressiv...

In what may become a significant breakthrough in bladder cancer treatment, UroGen Pharma Ltd. the Princeton-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) s acceptance of their Ne...

In a significant stride for both UroGen Pharma Ltd. and the realm of oncology, the company has announced the U.S. Food and Drug Administration’s (FDA) acceptance of its New Drug Application (NDA) for UGN-102, an investi...

In a significant milestone for bladder cancer treatment, UroGen Pharma Ltd. (Nasdaq: URGN) has announced the dosing of the first patient in its Phase 3 clinical trial for UGN-103, an innovative mitomycin-based formulati...

In a landmark announcement, UroGen Pharma Ltd. (Nasdaq: URGN), a pioneering biopharmaceutical company focused on developing innovative therapies for urothelial and specialty cancers, has officially submitted a New Drug...

UroGen Pharma Announces Commencement of Public Offering: Assessing the Impact on Company SharesUroGen Pharma Ltd., a biotech company focusing on innovative solutions for urothelial and specialty cancers, recently announ...

Breaking Boundaries in Urothelial Cancer Treatment: UroGen’s Innovations Show Promising Results By In the relentless quest to redefine cancer treatment, UroGen Pharma Ltd. (Nasdaq: URGN) has been making groundbreaking s...

A new analysis of real-world clinical data released by UroGen Pharma Ltd., a leading biotech company focused on developing novel treatment solutions for urothelial and specialty cancers, reveals that JELMYTO (mitomycin...

In a recent study, UroGen Pharma Ltd. presented the results of their analysis of the ATLAS trial, evaluating the sustained response rates of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (...

New Study Shows Promising Results for JELMYTO as Treatment for Low-Grade Upper Tract Urothelial Cancer: Comparable Complete Response Rate and Lower Stricture Incidence Compared to OLYMPUS Pivotal TrialPrinceton, N.J. -...